Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Essential Thrombocythemia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Essential Thrombocythemia Pipeline Outlook Report
In August 2025:- Icahn School of Medicine at Mount Sinai conducted a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary Essential Thrombocythemia (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks).
DelveInsight's Essential Thrombocythemia pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Essential Thrombocythemia treatment.
The leading Essential Thrombocythemia Companies such as PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Promising Essential Thrombocythemia Pipeline Therapies such as Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others.
Discover how the Essential Thrombocythemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Essential Thrombocythemia Clinical Trials and Studies
Essential Thrombocythemia Emerging Drugs Profile
Ropeginterferon alfa-2b: PharmaEssentia
Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon (ATC L03AB15). Its pharmacokinetic properties offer a new level of tolerability. Ropeginterferon alfa-2b is designed to be self-administered subcutaneously with a pen once every two weeks, or monthly during long-term maintenance. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of ET.
The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy.
IMG-7289: Imago Biosciences
IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Essential Thrombocythemia, and Polycythaemia Vera. The Drug has been granted orphan and fast track designation from US FDA.
The Essential Thrombocythemia Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment.
Essential Thrombocythemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market.
Get a detailed analysis of the latest innovations in the Essential Thrombocythemia pipeline. Explore DelveInsight's expert-driven report today! @ Essential Thrombocythemia Unmet Needs
Essential Thrombocythemia Companies
PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Essential Thrombocythemia Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Essential Thrombocythemia Therapies and key Developments @ Essential Thrombocythemia Market Drivers and Barriers, and Future Perspectives
Scope of the Essential Thrombocythemia Pipeline Report
Coverage- Global
Essential Thrombocythemia Companies- PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Essential Thrombocythemia Pipeline Therapies- Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others.
Essential Thrombocythemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Essential Thrombocythemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Essential Thrombocythemia drug development? Find out in DelveInsight's exclusive Essential Thrombocythemia Pipeline Report—access it now! @ Essential Thrombocythemia Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Essential Thrombocythemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Ropeginterferon alfa-2b: PharmaEssentia
Mid Stage Products (Phase II)
IMG-7289: Imago Biosciences
Early stage products (Phase I/II)
Drug Name: Company Name
Inactive Products
Essential Thrombocythemia Key Companies
Essential Thrombocythemia Key Products
Essential Thrombocythemia- Unmet Needs
Essential Thrombocythemia- Market Drivers and Barriers
Essential Thrombocythemia- Future Perspectives and Conclusion
Essential Thrombocythemia Analyst Views
Essential Thrombocythemia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/essential-thrombocythemia-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
21 minutes ago
- National Post
Samsara to Announce Second Quarter Fiscal Year 2026 Financial Results on September 4, 2025
SAN FRANCISCO — Samsara Inc. ('Samsara') (NYSE: IOT), the pioneer of the Connected Operations® Platform, today announced that it will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, after the U.S. market closes on Thursday, September 4, 2025. Samsara will host a live webcast that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors : Samsara's Second Quarter Fiscal Year 2026 Financial Results : Thursday, September 4, 2025 : 2:00 p.m. Pacific time (5:00 p.m. Eastern time) A webcast replay will be accessible from the Samsara investor relations website at The press release will be available on the Samsara investor relations website prior to the commencement of the event. Samsara (NYSE: IOT) is the pioneer of the Connected Operations® Platform, which enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world's leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. The company's mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy. View source version on
Globe and Mail
21 minutes ago
- Globe and Mail
Dow leaps 585 points as US stocks win back most of Friday's wipeout
NEW YORK (AP) — U.S. stocks rallied on Monday and won back most of their sharp loss from last week, when worries about how President Donald Trump's tariffs may be punishing the economy sent a shudder through Wall Street. The S&P 500 jumped 1.5% to follow up its worst day since May with its best since May. The Dow Jones Industrial Average climbed 585 points, or 1.3%, and the Nasdaq composite leaped 2%. Idexx Laboratories helped lead the way and soared 27.5% after the seller of veterinary instruments and other health care products reported a stronger profit for the spring than analysts expected. It also raised its forecast for profit over the full year. Tyson Foods likewise delivered a bigger-than-expected profit for the latest quarter, and the company behind the Jimmy Dean and Hillshire Farms brands rose 2.4%. They helped make up for a nearly 3% loss for Berkshire Hathaway after Warren Buffett's company reported a drop in profit for its latest quarter from a year earlier. The drop-off was due in part to the falling value of its investment in Kraft Heinz. The pressure is on U.S. companies to deliver bigger profits after their stock prices shot to record after record recently. The jump in stock prices from a low point in April raised criticism that the broad market had become too expensive. Stocks are coming off their worst week since May not so much because of that criticism but because of worries that Trump's tariffs may be hitting the U.S. economy following a longer wait than some economists had expected. Job growth slowed sharply last month, and the unemployment rate worsened to 4.2%. Trump reacted to Friday's disappointing jobs numbers by firing the person in charge of compiling them. He also continued his criticism of the Federal Reserve, which could lower interest rates in order to pump adrenaline into the economy. The Fed has instead been keeping rates steady this year, in part because lower rates can send inflation higher, and Trump's tariffs may be set to increase prices for U.S. households. Friday's stunningly weak jobs report did raise expectations on Wall Street that the Fed will cut interest rates at its next meeting in September. That caused Treasury yields to slump in the bond market, and they eased a bit more on Monday. The yield on the 10-year Treasury slipped to 4.19% from 4.23% late Friday. 'In our view, if the Fed starts to cut rates at its September meeting, we believe this would be supportive for markets,' according to David Lefkowitz, head of US equities at UBS Global Wealth Management. Such hopes, combined with profit reports from big U.S. companies that have largely come in better than expected, could help steady a U.S. stock market that may have been due for some turbulence. Before Friday, the S&P 500 had gone more than a month without a daily swing of 1%, either up or down. This upcoming week may feature fewer fireworks following last week's jobs report and profit updates from some of Wall Street's most influential companies. This week's highlights will likely include earnings reports from The Walt Disney Co., McDonald's and Caterpillar, along with updates on U.S. business activity. On Wall Street, American Eagle Outfitters jumped 23.6% after Trump weighed in on the debate surrounding the retailer's advertisements, which highlight actor Sydney Sweeney's great jeans. Some critics thought the reference to the blonde-haired and blue-eyed actor's 'great genes' may be extolling a narrow set of beauty standards. 'Go get 'em Sydney!' Trump said on his social media network. Wayfair climbed 12.7% after the retailer of furniture and home decor said accelerating growth helped it make more in profit and revenue during the spring than analysts expected. Tesla rose 2.2% after awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion. The move could remove potential worries that Musk may leave the company. CommScope soared 86.3% after reaching a deal to sell its connectivity and cable business to Amphenol for $10.5 billion in cash, while Amphenol rose 4.1%. They helped offset a 15.6% loss for On Semiconductor, which only matched analysts' expectations for profit in the latest quarter. The company, which sells to the auto and industrial industries, said it's beginning to see 'signs of stabilization' across its customers. All told, the S&P 500 rose 91.93 points to 6,329.94. The Dow Jones Industrial Average climbed 585.06 to 44,173.64, and the Nasdaq composite leaped 403.45 to 21,053.58. In stock markets abroad, indexes rose across much of Europe and Asia. South Korea's Kospi rose 0.9%, and France's CAC 40 climbed 1.1%, while Japan's Nikkei 225 was an outlier with a drop of 1.2%.
Globe and Mail
21 minutes ago
- Globe and Mail
Why Rocket Lab Might Be the Next SpaceX -- but With a Catch
Rocket Lab (NASDAQ: RKLB) is up 800% in just 12 months, riding a wave of hype, defense contracts, and bold ambitions to challenge SpaceX. But with no profits and an extreme valuation, is it a breakthrough or a bubble? Watch this before you invest. Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 4, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you invest $1,000 in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy. Rick Orford
